FR2741077B1 - Vaccin polyvalent anti-dengue - Google Patents

Vaccin polyvalent anti-dengue

Info

Publication number
FR2741077B1
FR2741077B1 FR9513489A FR9513489A FR2741077B1 FR 2741077 B1 FR2741077 B1 FR 2741077B1 FR 9513489 A FR9513489 A FR 9513489A FR 9513489 A FR9513489 A FR 9513489A FR 2741077 B1 FR2741077 B1 FR 2741077B1
Authority
FR
France
Prior art keywords
dengue vaccine
versatile anti
versatile
dengue
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9513489A
Other languages
English (en)
Other versions
FR2741077A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9513489A priority Critical patent/FR2741077B1/fr
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to CA002235334A priority patent/CA2235334A1/fr
Priority to PCT/FR1996/001801 priority patent/WO1997018311A1/fr
Priority to JP9518632A priority patent/JP2000500969A/ja
Priority to KR1019980703604A priority patent/KR19990067581A/ko
Priority to EP96939121A priority patent/EP0861324A1/fr
Priority to CN96198317A priority patent/CN1202201A/zh
Priority to AU76286/96A priority patent/AU718740B2/en
Priority to BR9611477-0A priority patent/BR9611477A/pt
Publication of FR2741077A1 publication Critical patent/FR2741077A1/fr
Application granted granted Critical
Publication of FR2741077B1 publication Critical patent/FR2741077B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9513489A 1995-11-14 1995-11-14 Vaccin polyvalent anti-dengue Expired - Fee Related FR2741077B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR9513489A FR2741077B1 (fr) 1995-11-14 1995-11-14 Vaccin polyvalent anti-dengue
PCT/FR1996/001801 WO1997018311A1 (fr) 1995-11-14 1996-11-14 Vaccin polyvalent anti-dengue
JP9518632A JP2000500969A (ja) 1995-11-14 1996-11-14 抗デング熱多価ワクチン
KR1019980703604A KR19990067581A (ko) 1995-11-14 1996-11-14 뎅그열에 대한 다가 백신
CA002235334A CA2235334A1 (fr) 1995-11-14 1996-11-14 Vaccin polyvalent anti-dengue
EP96939121A EP0861324A1 (fr) 1995-11-14 1996-11-14 Vaccin polyvalent anti-dengue
CN96198317A CN1202201A (zh) 1995-11-14 1996-11-14 抗登革热的多价疫苗
AU76286/96A AU718740B2 (en) 1995-11-14 1996-11-14 Polyvalent anti-dengue vaccine
BR9611477-0A BR9611477A (pt) 1995-11-14 1996-11-14 Polipeptìdeo ou glicopeptìdeo, composições aptas a estimular a imunidade, sequência, e vetor, de ácidos nucleicos, vetor de expressão, processo de preparação de um polipeptìdeo ou glicopeptìdeo, vacina polivalente contr5a o vìrus da dengue e composição antigênica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9513489A FR2741077B1 (fr) 1995-11-14 1995-11-14 Vaccin polyvalent anti-dengue

Publications (2)

Publication Number Publication Date
FR2741077A1 FR2741077A1 (fr) 1997-05-16
FR2741077B1 true FR2741077B1 (fr) 1998-01-23

Family

ID=9484557

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9513489A Expired - Fee Related FR2741077B1 (fr) 1995-11-14 1995-11-14 Vaccin polyvalent anti-dengue

Country Status (9)

Country Link
EP (1) EP0861324A1 (fr)
JP (1) JP2000500969A (fr)
KR (1) KR19990067581A (fr)
CN (1) CN1202201A (fr)
AU (1) AU718740B2 (fr)
BR (1) BR9611477A (fr)
CA (1) CA2235334A1 (fr)
FR (1) FR2741077B1 (fr)
WO (1) WO1997018311A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
AU752191B2 (en) 1997-07-31 2002-09-12 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
FR2767324B1 (fr) * 1997-08-14 2001-04-06 Pasteur Institut Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
EP1978027B1 (fr) * 2000-02-10 2012-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Clones d' ADNc infectieux complets de flavivirus transmis par des tiques
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
JP6983653B2 (ja) * 2014-09-01 2021-12-17 インターナショナル センター フォー ジェネティック エンジニアリング アンド バイオテクノロジー ワクチン
US10946087B2 (en) * 2014-09-02 2021-03-16 Sanofi Pasteur Vaccine compositions against dengue virus diseases
CN106290847A (zh) * 2015-05-13 2017-01-04 上海凯创生物技术有限公司 一种登革热病毒ns1抗原乳胶法检测试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003161A1 (fr) * 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Proteines d'enveloppe de flavivirus avec pouvoir immunogene accru utilisables dans l'immunisation contre les infections virales
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease

Also Published As

Publication number Publication date
JP2000500969A (ja) 2000-02-02
KR19990067581A (ko) 1999-08-25
CA2235334A1 (fr) 1997-05-22
FR2741077A1 (fr) 1997-05-16
CN1202201A (zh) 1998-12-16
WO1997018311A1 (fr) 1997-05-22
AU7628696A (en) 1997-06-05
EP0861324A1 (fr) 1998-09-02
BR9611477A (pt) 1999-12-28
AU718740B2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
PT810877E (pt) Vacina da hepatite b
NO20003302L (no) Vaksine
FR2629717B1 (fr) Preparation de vaccin
DZ2462A1 (fr) Vaccin antigrippal.
NO996133D0 (no) Olje-i-vann-vaksinesammensetninger
DE59601148D1 (de) Belustigungsvorrichtung
BR9609258A (pt) Vacinas contra hepatite c
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
BR9609352A (pt) Tecido de malho cirùrgico
DE69634161D1 (de) Gewebe-Aufzeigevorrichtung
DE69625368D1 (de) Schweisshemmende deodorierende präparaten
DE69601561D1 (de) Chirurgische Klammersetzvorrichtung
BR9605563A (pt) Andador dobrável
DZ2283A1 (fr) Composition de vaccin.
BR9604906A (pt) Agentes anti-fúngicos de peptídeo cíclico
DE69615631D1 (de) Kultivator
FR2741077B1 (fr) Vaccin polyvalent anti-dengue
FR2715304B1 (fr) Vaccin anti-allergique.
ITMI950676A0 (it) Vaccini polinucleotidici
NL300165I1 (nl) Babesiavaccine.
KR960026504U (ko) 넥타이
KR970000260U (ko) 의자용 다리부의 결합장치
KR970009549U (ko) 의료기구 포장장치
DE69326536D1 (de) Antitumor Impfstoff

Legal Events

Date Code Title Description
CD Change of name or company name
CL Concession to grant licences
ST Notification of lapse
ST Notification of lapse